June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
DIABETIC MACULAR EDEMA IN NAIVE PATIENTS TREATED BY INTRAVITREAL OZURDEX IN CLINICAL PRACTICE: The “DIMENTION” Study.
Author Affiliations & Notes
  • Despreaux Raphaelle
    Paris, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
  • Sara Touhami
    Pitié Salpétrière Hospital, Paris, France
  • Clémence Virevialle
    Paris, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
  • Raphaël Adam
    Paris, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
  • Jean Philippe Nordmann
    Paris, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
  • Jad Akesbi
    Paris, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
  • Footnotes
    Commercial Relationships   Despreaux Raphaelle, None; Sara Touhami, None; Clémence Virevialle, None; Raphaël Adam, None; Jean Philippe Nordmann, None; Jad Akesbi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 913. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Despreaux Raphaelle, Sara Touhami, Clémence Virevialle, Raphaël Adam, Jean Philippe Nordmann, Jad Akesbi; DIABETIC MACULAR EDEMA IN NAIVE PATIENTS TREATED BY INTRAVITREAL OZURDEX IN CLINICAL PRACTICE: The “DIMENTION” Study.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):913.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the “real-life” efficacy and safety outcomes of intravitreal dexamethasone (DEX) implant as first line treatment in diabetic macular edema (DME).

Methods : Retrospective study of 31 consecutive patients (45 eyes) with DME treated by DEX implant as first-line therapy. Main outcome measures included the evolution of best-corrected visual acuity (BCVA) and central foveal thickness (CFT) overtime, retreatment interval and tolerance profile.

Results : Overall, 2.53 ± 1.9 DEX implants were administrated over a 3-year follow-up period and 29 eyes (64.4%) received multiple injections (≥ 2). BCVA gains as compared to baseline values were +9.5 letters (p = 0.007), +15.4 letters (p = 0.03) and +9.9 letters (p = 0.18) respectively after 12, 24 and 36 months. Mean BCVA increased by an average of +7.8 letters (p < 0.0001), +5.8 letters (p = 0.004), +7.1 letters (p = 0.007) and +1.2 letters (p = 0.79) respectively 1, 3, 6 and 12 months after the latest DEX injection. Mean CFT decreased by -196.8 mm (p < 0.0001), -168.3 mm (p < 0.0001), - 97.6 mm (p = 0.006) and –41 mm (p = 0.27) respectively 1, 3, 6 and 12 months after the latest DEX injection. Seven eyes (15.6%) showed transient increase of intraocular pressure and 68% of phakic eyes underwent cataract surgery during the follow-up.

Conclusions : DEX implant allows long-term functional and anatomical improvement in naïve patients with DME with a good safety profile in real-life practice.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×